Clinical outcomes of umbilical cord blood transplantation for AML patients in the era of FLT3 inhibitors

Clinical outcomes of umbilical cord blood transplantation for AML patients in the era of FLT3 inhibitors - Maintenance therapy using FLT3 inhibitors after UCBT in AML

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230158

Enrollment

200

Registered

2023-06-24

Start date

2023-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeolid leukemia acute myeloid leukemia, FLT3-mutation, gilteritinib

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult AML patients who received UCBT in Toranomon Hospital between January 1st, 2019 and December 31st, 2023.

Exclusion criteria

Exclusion criteria: Patients who declared not to participate the study.

Design outcomes

Primary

Measure	Time frame
1-year-progression-free survival in AML patients after UCBT	—

Secondary

Measure	Time frame
1- and 5-year-cumulative incidence of relapse after UCBT 1- and 5-year-cumulative incidence of NRM after UCBT 1- and 5-year-cumulative incidence of overall survival after UCBT 1- and 5-year-cumulative incidence of viral infection (CMV, EBV, HHV-6) after UCBT 1- and 5-year-cumulative incidence of acute GVHD after UCBT 1- and 5-year-cumulative incidence of chronic GVHD after UCBT	—

Contacts

Public ContactNaoyuki Uchida

Toranomon Hospital

nuchida@toranomon.gr.jp+81-3-3588-1111

Outcome results